Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis.

Autor: de la Borderie G; UCB, 420 rue d'Estienne d'Orves, Colombes 92700, France., Chimits D; UCB, Colombes, France., Boroojerdi B; UCB, Monheim, Germany., Brock M; UCB, Morrisville, NC, USA., Duda PW; UCB, Cambridge, MA, USA., Grimson F; UCB, Slough, UK., Mahoney P; UCB, Slough, UK., Strimenopoulou F; UCB, Slough, UK., Cutter G; Department of Biostatistics, The University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA., Aban I; Department of Biostatistics, The University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA., Brauner S; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Department of Neurology, Karolinska University Hospital, Stockholm, Sweden., Petersson M; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Howard JF Jr; Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Bennett N; UCB, Morrisville, NC, USA.

Publikováno v: Therapeutic advances in neurological disorders [Ther Adv Neurol Disord] 2024 Sep 21; Vol. 17, pp. 17562864241279125. Date of Electronic Publication: 2024 Sep 21 (Print Publication: 2024).

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study.

Autor: Howard JF Jr; Department of Neurology, UNC School of Medicine, The University College of North Carolina at Chapel Hill, 2200 Houpt Building, CB#7025, 170 Manning Drive, Chapel Hill, NC 27599-7025, USA., Bresch S; Service de Neurologie, Hospital Pasteur, Centre Hospitalier Universitaire de Nice, Nice, France., Farmakidis C; Neuromuscular Division, Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA., Freimer M; Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Genge A; Clinical Research Unit, Montreal Neurological Institute, Montreal, QC, Canada., Hewamadduma C; Academic Neuroscience Unit, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK.; Sheffield Institute for Translational Neurosciences (SITRAN), University of Sheffield, Sheffield, UK., Hinton J; Department of Neurology, Frederick P. Whiddon School of Medicine, University of South Alabama, Mobile, AL, USA., Hussain Y; Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Juntas-Morales R; Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain., Kaminski HJ; Department of Neurology and Rehabilitation Medicine, George Washington University, Washington, DC, USA., Maniaol A; Department of Neurology, Oslo University Hospital, Oslo, Norway., Mantegazza R; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy., Masuda M; Department of Neurology, Tokyo Medical University, Tokyo, Japan., Nowak RJ; Department of Neurology, Yale School of Medicine, New Haven, CT, USA., Sivakumar K; Neuromuscular Clinic and Research Center, Phoenix, AZ, USA., Śmiłowski M; Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland., Utsugisawa K; Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan., Vu T; Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA., Weiss MD; Department of Neurology, University of Washington Medical Center, Seattle, WA, USA., Zajda M; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland., Bloemers J; UCB Pharma, Brussels, Belgium., Boroojerdi B; UCB Pharma, Monheim am Rhein, Germany., Brock M; UCB Pharma, Raleigh, NC, USA., de la Borderie G; UCB Pharma, Brussels, Belgium., Duda PW; UCB Pharma, Cambridge, MA, USA., Vanderkelen M; UCB Pharma, Braine-L'Alleud, Belgium., Leite MI; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Publikováno v: Therapeutic advances in neurological disorders [Ther Adv Neurol Disord] 2024 Apr 17; Vol. 17, pp. 17562864241243186. Date of Electronic Publication: 2024 Apr 17 (Print Publication: 2024).

Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.

Autor: Kulasekararaj AG; King's College Hospital-NHS Foundation Trust, NIHR/Wellcome King's Clinical Research Facility, London, UK and King's College London, London., Lehtinen AE; Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki., Forsyth C; Gosford Hospital, Gosford, NSW., Gandhi S; King's College Hospital-NHS Foundation Trust, NIHR/Wellcome King's Clinical Research Facility, London, UK and King's College London, London., Griffin M; St. James's University Hospital, Leeds., Körper S; University of Ulm, Institute of Transfusion Medicine, and Institute of Transfusion Medicine and Immunogenetics Ulm, Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm., Mikala G; Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest., Muus P; King's College Hospital-NHS Foundation Trust, NIHR/Wellcome King's Clinical Research Facility, London, UK and King's College London, London, UK; St. James's University Hospital, Leeds., Overgaard U; University Hospital Copenhagen, Copenhagen, Denmark., Patriquin CJ; University Health Network, Toronto, ON., Pullon H; Waikato Hospital, Hamilton., Shen YM; UT Southwestern Medical Center, Dallas, TX., Spearing R; Christchurch Hospital, Christchurch., Szer J; Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC., De la Borderie G; Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC., Duda PW; UCB Pharma, Cambridge, MA., Farzaneh-Far R; UCB Pharma, Cambridge, MA., Ragunathan S; UCB Pharma, Cambridge, MA., Sayegh CE; UCB Pharma, Cambridge, MA., Vadysirisack DD; UCB Pharma, Cambridge, MA., Schrezenmeier H; University of Ulm, Institute of Transfusion Medicine, and Institute of Transfusion Medicine and Immunogenetics Ulm, Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm. h.schrezenmeier@blutspende.de.

Publikováno v: Haematologica [Haematologica] 2024 Mar 01; Vol. 109 (3), pp. 929-935. Date of Electronic Publication: 2024 Mar 01.

Score fluctuation might be associated with a higher placebo rate in the RAISE trial - Authors' reply.

Autor: Howard JF Jr; Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7025, USA. Electronic address: howardj@neurology.unc.edu., Boroojerdi B; UCB Pharma, Monheim, Germany., de la Borderie G; UCB Pharma, Monheim, Germany., Leite MI; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK., Utsugisawa K; Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.

Publikováno v: The Lancet. Neurology [Lancet Neurol] 2023 Nov; Vol. 22 (11), pp. 982-983.

More new cancers in type 2 diabetes with diabetic foot disease: A longitudinal observational study.

Autor: Alkhami F; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France., Borderie G; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France., Foussard N; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France., Larroumet A; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France., Blanco L; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France., Barbet-Massin MA; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France., Ferrière A; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France., Ducos C; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France., Domenge F; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France., Mohammedi K; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France., Rigalleau V; Bordeaux CHU and University, Endocrinology-Diabetology-Nutrition, 33000, Bordeaux, France. Electronic address: vincent.rigalleau@chu-bordeaux.fr.

Publikováno v: Diabetes & metabolic syndrome [Diabetes Metab Syndr] 2023 Oct; Vol. 17 (10), pp. 102859. Date of Electronic Publication: 2023 Sep 27.